Clinical Trials Logo

Ann Arbor Stage III Grade 1 Follicular Lymphoma clinical trials

View clinical trials related to Ann Arbor Stage III Grade 1 Follicular Lymphoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT00740805 Active, not recruiting - Solid Neoplasm Clinical Trials

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

Start date: August 18, 2008
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib, cyclophosphamide, and doxorubicin hydrochloride when given together in treating patients solid tumors or non-Hodgkin lymphoma that has spread to other areas of the body or cannot be removed by surgery. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, cyclophosphamide, and doxorubicin hydrochloride may kill more cancer cells.